Biohaven reports 1,000-option grant at $12.34

Biohaven Ltd. disclosed an indirect stock option grant tied to the SVP of Clinical Operations’ son, with the officer disclaiming beneficial ownership.

Rhea-AI Filing Summary

Biohaven Ltd. (BHVN) reported that officer Kimberly Gentile, SVP, Clinical Operations, had a stock option grant reported in her name for 1,000 options to purchase Biohaven common shares at an exercise price of $12.34 per share, expiring September 15, 2036. The option was granted in connection with her son's employment and is held indirectly "By Son", with vesting in four equal installments on September 15 of 2026, 2027, 2028 and 2029, subject to his continuous service. Gentile disclaims beneficial ownership of all securities held by her son, and no Rule 10b5-1 trading plan is reported.

Insider Trade Summary

Grant/Award: 1,000 shares

Grant/Award 1 txn

Insider Gentile Kimberly

Role SVP, Clinical Operations

Type	Security	Shares	Price	Value
Grant/Award	Stock Options (Right to buy) F1, F2	1,000	$0.00	$0.00

Holdings After Transaction: Stock Options (Right to buy) — 1,000 contracts (Indirect, By Son)

Footnotes (2)

1. F1. The shares underlying this option vest in four equal installments on September 15, 2026, 2027, 2028 and 2029, subject to the Reporting Person's son's continuous service with the Issuer at each vesting date.
2. F2. Represents a stock option granted to the Reporting Person's son in connection with the commencement of his employment with the Issuer. The Reporting Person disclaims beneficial ownership of all securities held by her son, and this report should not be deemed an admission that the Reporting Person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose.

Key Figures

Stock options granted: 1,000 options Exercise price: $12.34 per share Expiration date: September 15, 2036 +2 more

5 metrics

Stock options granted 1,000 options Stock options (right to buy) reported for September 15, 2026 grant date

Exercise price $12.34 per share Exercise price of the 1,000 stock options to purchase common shares

Expiration date September 15, 2036 Expiration of the reported stock option grant

Underlying common shares 1,000 shares Common shares underlying the reported stock options

Vesting schedule 4 installments in 2026, 2027, 2028, 2029 Equal vesting on September 15 of each year, subject to continuous service

Key Terms

Stock Options (Right to buy), beneficial ownership, Section 16, continuous service

4 terms

Stock Options (Right to buy) financial

"security title is listed as Stock Options (Right to buy)"

beneficial ownership financial

"The Reporting Person disclaims beneficial ownership of all securities"

Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.

Section 16 regulatory

"beneficial owner of such securities for purposes of Section 16"

Section 16 is a U.S. securities law rule that governs the trading and disclosure obligations of company insiders — typically officers, directors and large shareholders — to promote transparency and deter unfair profit-taking. It requires insiders to publicly report their stock trades and allows companies or the issuer to reclaim quick, short-term profits from certain insider trades, like a scoreboard and a refund policy that help investors see and limit possible insider advantage.

continuous service other

"subject to the Reporting Person's son's continuous service with the Issuer"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did BHVN disclose for Kimberly Gentile?

Biohaven disclosed a grant of 1,000 stock options reported for SVP, Clinical Operations, Kimberly Gentile, relating to her son’s employment. The options allow purchase of Biohaven common shares at an exercise price of $12.34 per share and expire on September 15, 2036.

Who is the actual holder of the 1,000 Biohaven (BHVN) stock options?

The 1,000 stock options are held indirectly by Kimberly Gentile’s son. The filing states they were granted to her son in connection with the commencement of his employment with Biohaven, and Gentile disclaims beneficial ownership of all securities held by her son.

What are the vesting terms of the 1,000 Biohaven (BHVN) stock options?

The options vest in four equal installments on September 15, 2026, 2027, 2028 and 2029. Vesting is subject to the son’s continuous service with Biohaven on each vesting date, as stated in the footnote.

What is the exercise price and expiration date of the Biohaven (BHVN) options reported?

The stock options have an exercise price of $12.34 per share and an expiration date of September 15, 2036. A total of 1,000 underlying common shares are associated with this option grant.

Does Kimberly Gentile report beneficial ownership of her son’s Biohaven (BHVN) options?

No. The filing states that Kimberly Gentile disclaims beneficial ownership of all securities held by her son and that the report should not be deemed an admission that she is the beneficial owner for Section 16 or any other purpose.

Was the Biohaven (BHVN) option grant made under a Rule 10b5-1 plan?

The filing indicates no Rule 10b5-1 trading plan. The document-level checkbox for such a plan is not marked as applicable, and the footnotes do not reference any pre-arranged trading plan for this option grant.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/17/2026 - 06:15 PM Accepted by SEC EDGAR 09/17/2026 - 06:15 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Gentile Kimberly

(Last) (First) (Middle)

C/O BIOHAVEN LTD.

215 CHURCH STREET

(Street)

NEW HAVEN CONNECTICUT 06510

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Biohaven Ltd. [ BHVN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	SVP, Clinical Operations

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/15/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Options (Right to buy)	$12.34	09/15/2026		A		1,000		(1)	09/15/2036	Common Shares	1,000	$0	1,000(2)	I	By Son

Explanation of Responses:

1. The shares underlying this option vest in four equal installments on September 15, 2026, 2027, 2028 and 2029, subject to the Reporting Person's son's continuous service with the Issuer at each vesting date.

2. Represents a stock option granted to the Reporting Person's son in connection with the commencement of his employment with the Issuer. The Reporting Person disclaims beneficial ownership of all securities held by her son, and this report should not be deemed an admission that the Reporting Person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose.

Remarks:

	/s/ George Clark, Attorney-in-Fact	09/17/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)